Supportive information Table 1:Descriptive statistic of study cohort. Shown is the preoperative data (abbreviations: ASAT = aspartate aminotransferase; GOT = glutamate oxalate transaminase; 5-FU=5-Fluoruracil).

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | | **n (%) for binary variables, otherwise mean (median, range)** | **Missing**  **values** |
| *Pre-operative details* | |  |  |
| Male gender | | 204 (63.16 %) | 0 (0.0%) |
| Age at resection in years | | 61.98 (63.54; 27.01-90.67) | 0 (0.0%) |
| Body mass index | | 26.69 (25.95; 17.51-53.63) | 0 (0.0%) |
| Hemoglobin in g/dl | | 13.64 (13.80; 9.30-17.10) | 2 (0.6%) |
| Leukocytes in tsd/µl | | 6.67 (6.50; 1.90-16.10) | 2 (0.6%) |
| Platelets in tsd/µl | | 238.04 (227.00;94.00-686.00) | 2 (0.6%) |
| Quick in % | | 99.59 (100.00; 52.00-145.00) | 2 (0.6%) |
| ASAT (GOT) in U/l | | 33.80 (28.50; 6.00-368.00) | 7 (2.2%) |
| Creatinine in µmol/l | | 71.42 (70.00; 42.00-127.00) | 9 (2.8%) |
| Resection severity index | | 1.11 (0.58; 0.06-15.39) | 9 (2.8%) |
| Fibrosis-4 score | | 1.70 (1.50; 0.35-5.60) | 76 (23.5%) |
|  |  |  |  |
| *Therapy of metastases* | |  |  |
| Neoadjuvant chemotherapy 5-FU + Oxaliplatin | | 25 (7.74%) | 0 (0.0%) |
| Neoadjuvant chemotherapy 5-FU + Irinotecan | | 25 (7.74%) |
| Neoadjuvant chemotherapy Other | | 5 (1.55%) |
|  |  |  |  |
| *Primary tumor characteristics* | |  |  |
| Location | Cecum | 18 (5.68%) | 6 (1.9%) |
| Colon ascendens | 39 (12.30%) |
| Colon transversum | 8 (2.52%) |
| Colon descendens | 16 (5.05%) |
| Colon sigmoideum | 102 (32.18%) |
| Rectum | 134 (42.27%) |
| UICC 7 stages | I | 14 (4.56%) | 16 (5.0%) |
| IIa | 36 (11.73%) |
| IIb | 2 (0.65%) |
| IIIa | 8 (2.61%) |
| IIIb | 60 (19.54%) |
| IIIc | 61 (19.87%) |
| IV | 126 (41.04%) |
| Tumor grading | G1 | 5 (1.69%) | 27 (8.4%) |
| G2 | 270 (91.22%) |
| G3 | 21 (7.10%) |
| R status | R0 | 297 (98.34%) | 21 (6.5%) |
| R1 | 5 (1.66%) |
| R2 | 0 (0.00%) |
| Neoadjuvant chemotherapy 5-FU | | 30 (9.29%) | 0 (0.0%) |
| Neoadjuvant chemotherapy 5-FU + Oxaliplatin | | 8 (2.48%) |
| Neoadjuvant chemotherapy Other | | 11 (3.41%) |
| Adjuvant chemotherapy 5-FU | | 108 (33.44%) |
| Adjuvant chemotherapy 5-FU + Oxaliplatin | | 99 (30.65%) |
| Adjuvant chemotherapy 5-FU + Irinotecan | | 10 (3.10%) |
| Adjuvant chemotherapy Other | | 35 (10.84%) |
| Conversion chemotherapy 5-FU | | 14 (4.33%) |
| Conversion chemotherapy 5-FU + Oxaliplatin | | 23 (7.12%) |
| Conversion chemotherapy 5-FU + Irinotecan | | 35 (10.84%) |
| Adjuvant radiation | | 74 (23.12%) | 3 (0.9%) |
| Local relapse of primary tumor | | 17 (5.26%) | 0 (0.0%) |